Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
Vedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. Although upper respiratory tract infections (URTIs) have been reported with VDZ [1] its gut selectivity may reduce the risk of respiratory tract infections (RT...
Πλήρης περιγραφή
Λεπτομέρειες βιβλιογραφικής εγγραφής
| Κύριοι συγγραφείς: |
Feagan, B,
Bhayat, F,
Khalid, J,
Palo, W,
Blake, A,
Shetzline, M,
Travis, S |
|---|
| Μορφή: | Journal article
|
|---|
| Έκδοση: |
Oxford University Press
2017
|
|---|